my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
18-06-2012: Sanaria Inc and the Institute for Bioscience and Biotechnology Research (IBBR) of the University of Maryland College Park announce the receipt of a multi-year Phase II Small Business Innovation Research (SBIR) Grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The grant, worth nearly $3 million over a 3 year period, will fund research and development to genetically engineer mosquitoes that produce large numbers of parasites for Sanaria's malaria vaccine manufacturing process. This Phase II SBIR award allows the continuation and expansion of a successful partnership supported by a Phase I SBIR. Malaria vaccine development is a major humanitarian objective. Malaria causes more than 200 million clinical cases and between 650,000 and 1.2 million deaths each year.
Dr. Peter F. Billingsley, Sanaria Senior Scientist and Principal Investigator on the grant states, "Sanaria and IBBR have established a powerful system with which to exploit new techniques in mosquito genetics and efficiently test the ability of modified mosquito strains to sustain high level P. falciparum infections." According to Dr. David O'Brochta, a Principal Investigator on the grant and Director of the Insect Transformation Facility at IBBR, "The partnership between Sanaria and IBBR supported by this grant is an extraordinary opportunity to continue to exploit the unique capabilities of our Insect Transformation Facility in pursuit of a goal of tremendous importance."
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Sanaria Inc and the Institute for Bioscience and Biotechnology Research (IBBR) of the University of Maryland College Park announce the receipt of a multi-year Phase II Small Business Innovation Research (SBIR) Grant from the National Institute of Allergy and Infectious Diseases (NIAID) of t ... more
Initial Trial of Sanaria's Malaria Vaccine Yields Positive Results
Positive results from the initial Phase 1 clinical trial in 80 healthy volunteers and complementary pre-clinical studies of the Sanaria® PfSPZ Vaccine are published in Science."This is the first indication that a highly effective malaria vaccine may be available that can be used to elimina ... more
Sanaria Inc. has received additional support from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health in the form of a Phase II Small Business Innovation Research (SBIR) Grant. The award for two years isUS$1.99 million. Subject to satisfact ... more
Hospital Cleaning Protocol Ineffective Against A. Baumannii
Current hospital cleaning protocol may be inadequate to rid patient rooms of multidrug-resistant (MDR) Acinetobacter baumannii, according to a study in the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiol ... more
Bacteria on marine sponges can develop capacity to move and inhibit biofilm formation
A new study shows that when enough bacteria get together in one place, they can make a collective decision to grow an appendage and swim away. This type of behavior has been seen for the first time in marine sponges, and could lead to an understanding of how to break up harmful bacterial bi ... more
Sanaria Inc and the Institute for Bioscience and Biotechnology Research (IBBR) of the University of Maryland College Park announce the receipt of a multi-year Phase II Small Business Innovation Research (SBIR) Grant from the National Institute of Allergy and Infectious Diseases (NIAID) of t ... more
Sanaria Inc and the Institute for Bioscience and Biotechnology Research (IBBR) of the University of Maryland College Park announce the receipt of a multi-year Phase II Small Business Innovation Research (SBIR) Grant from the National Institute of Allergy and Infectious Diseases (NIAID) of t ... more
NIH renews research program to develop medical countermeasures against radiological, nuclear threats
A major research effort to develop medical products to diagnose, prevent and treat the short- and long-term consequences of radiation exposure after a radiological or nuclear terrorist attack has been renewed by the National Institute of Allergy and Infectious Diseases (NIAID), part of the ... more
New approach to immune cell analysis seen as first step to better distinguish health and disease
Investigators have developed a new mathematical approach to analyze molecular data derived from complex mixtures of immune cells. This approach, when combined with well-established techniques, readily identifies changes in small samples of human whole blood, and has the potential to disting ... more
National Institute of Allergy and Infectious Diseases (NIAID)
The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. For more than 60 years, NIAID research has led to new therapies, vaccines, d ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
